GID BIO IN THE NEWS
Read how recent cell-based therapy discoveries are impacting the field of medicine.
New Jersey Regenerative Institute begins enrolling patients for GID BIO’s pivotal/Phase III clinical trial testing cellular therapy for knee osteoarthritis
Gerry Malanga, M.D., recent president of Interventional Orthobiologics Foundation, is the second principal investigator in our FDA-compliant pivotal/Phase III clinical
Denver Business Journal features GID BIO: “Colorado biotech firm’s new cell therapy could eliminate the need for knee replacements”
As the total number of confirmed COVID-19 cases surpasses five million in the US, companies across the country are researching
Late-stage biotech GID BIO wins funding from Richard King Mellon Foundation to study cellular therapy as a potential therapeutic for severe respiratory distress
Study to treat hospitalized COVID-19 patients applies same technology platform and point-of-care cellular therapy used in a pivotal/Phase III trial
Former Yahoo! Chairman, Wall Street Titan Roy J. Bostock Joins GID BIO as Chair
Bostock joins late-stage biotech as pivotal Phase III trial gets underway for cellular therapy for osteoarthritis of the knee LOUISVILLE,
GID BIO seeks up to USD 25m to support cellular therapy platform, CEO says
Mergermarket is the leading provider of forward-looking M&A intelligence and data to investment banks, private equity firms, law firms, accounting
An interview with William Cimino, PhD, CEO GID BIO, International Federation for Adipose Therapeutics and Science (IFATS) Annual Conference in Marseille, France
GID BIO completed a pivotal Phase IIb clinical trial with an FDA-compliant study design using autologous stromal cells in the
6 Orthobiologic Companies Move Clinical Trials Forward
Multiple orthobiologic companies have engaged in clinical trials in 2019, seeking to demonstrate the efficacy of their cell-based products…. GID BIO completed a
GID BIO Completes Trial of Stromal Cells to Treat Knee OA
GID BIO completed a pivotal Phase IIb clinical trial with an FDA-approved study design using autologous stromal cells in the
